Lenalidomide: all 818 studies that test it

Page 2 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.

• Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 1
• A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
• MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)RecruitingNCT04110301Phase 1/2
• Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaRecruitingNCT03746223Phase 2
• R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
• VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
• Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT03523975Phase 1/2
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
• A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150091Phase 1/2Results posted
• A Study of Tafasitamab and Lenalidomide in People With Mantle Cell LymphomaTerminatedNCT05788289Phase 2Results posted
• Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
• A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
• Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsActive, not recruitingNCT05222555Phase 1/2Results posted
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemActive, not recruitingNCT05211336Phase 1Results posted
• MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedNCT05090566Phase 2Results posted
• Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedNCT05032820Phase 2Results posted
• To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2Results posted
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
• Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaCompletedNCT03934684Phase 4Results posted
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted
• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT03702725Phase 1Results posted
• To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03544281Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyCompletedNCT03416374Phase 4Results posted
• Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideTerminatedNCT03411031Phase 2Results posted
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaCompletedNCT03409432Phase 2Results posted
• Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03333746Phase 2Results posted
• A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03290950Phase 2Results posted
• PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaCompletedNCT03269136Phase 1Results posted
• Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03118466Phase 2Results posted
• Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS TumorsTerminatedNCT03050450Phase 1Results posted
• Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 1Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell LymphomaCompletedNCT03003520Phase 2Results posted
• Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedNCT02969837Phase 2Results posted
• Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung CancerTerminatedNCT02963610Phase 1/2Results posted
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedNCT02954406Phase 1Results posted
• High Dose Carfilzomib for Newly Diagnosed MyelomaCompletedNCT02937571Phase 1/2Results posted
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02917941Phase 2Results posted
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaCompletedNCT02916771Phase 2Results posted
• Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaActive, not recruitingNCT02911142Phase 1/2Results posted
• Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaTerminatedNCT02898259Phase 1/2Results posted
• Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantCompletedNCT02880228Phase 2Results posted
• Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin LymphomaTerminatedNCT02875067Phase 1/2Results posted
• Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular LymphomaCompletedNCT02871219Phase 2Results posted
• Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2Results posted
• Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementCompletedNCT02765854Phase 2Results posted
• Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaCompletedNCT02633137Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaCompletedNCT02631577Phase 1/2Results posted
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT02628405Phase 1/2Results posted
• Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02619682Phase 2Results posted
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
• Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/2Results posted
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02538965Phase 2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
• Lenalidomide for Adult Histiocyte DisordersActive, not recruitingNCT02523040Phase 2Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of BoneTerminatedNCT02516423Phase 3Results posted
• Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaCompletedNCT02481934Phase 1Results posted
• Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell LymphomaActive, not recruitingNCT02446457Phase 2Results posted
• Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT02446236Phase 1Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLCompletedNCT02399085Phase 2Results posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseTerminatedNCT02370888Phase 1Results posted
• Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT02353468Phase 2Results posted
• Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedNCT02341014Phase 1/2Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)CompletedNCT02322320Phase 3Results posted
• Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell LymphocytosisTerminatedNCT02309515Phase 2Results posted
• Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell LymphomaCompletedNCT02285062Phase 3Results posted
• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingNCT02253316Phase 2Results posted
• Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT02225275Phase 2Results posted
• Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasCompletedNCT02213913Phase 1/2Results posted
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCompletedNCT02159365Phase 2Results posted
• Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT02142049Phase 1/2Results posted
• Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in RemissionCompletedNCT02126553Phase 2Results posted
• Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02086552Phase 2Results posted
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
• Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT02075021Phase 1/2Results posted
• Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell DyscrasiasCompletedNCT02041325Phase 2Results posted
• Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantTerminatedNCT02038153Phase 1/2Results posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01995669Phase 1/2Results posted
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)CompletedNCT01938001Phase 3Results posted
• Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)TerminatedNCT01927718Not applicableResults posted
• Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01924169Phase 2Results posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaCompletedNCT01919086Phase 2Results posted
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaTerminatedNCT01881789Phase 1/2Results posted
• Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell LymphomaActive, not recruitingNCT01856192Phase 2Results posted
• WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationCompletedNCT01827137Phase 1/2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01816971Phase 2Results posted

← Lenalidomide overview